Skip to contentP
Pure Bioscience, Inc.
P
PUREPure Bioscience, Inc. Q3 2022 · 10-Q
Revenue$524.00K$524.00K−6.6% vs Q3 2021 Net Income-$760.00K-$760.00KN/M vs Q3 2021 EPS, diluted—
Gross Profit$325,000+3.2% Operating Income-$759,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pure Bioscience, Inc. · CIK 1006028 · Engraved from SEC EDGAR
Operating Cash Flowderived-$609,000N/M Free Cash Flowderived-$620,000N/M Margins · derivedGross margin62.0%+5.9 pt vs Q3 2021
Operating margin-144.8%−0.5 pt vs Q3 2021
Net margin-145.0%−0.5 pt vs Q3 2021
ended Apr 30, 2022 · filed Jun 14, 2022 · 45 d after period end